HC Wainwright Forecasts Strong Price Appreciation for Intellia Therapeutics (NASDAQ:NTLA) Stock

Intellia Therapeutics (NASDAQ:NTLA) had its target price increased by investment analysts at HC Wainwright from $25.00 to $30.00 in a research note issued to investors on Tuesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target indicates a potential upside of 117.08% from the stock’s previous close. HC Wainwright also issued estimates for Intellia Therapeutics’ Q1 2026 earnings at ($0.97) EPS, Q2 2026 earnings at ($0.88) EPS, Q3 2026 earnings at ($0.96) EPS, Q4 2026 earnings at ($0.91) EPS and FY2026 earnings at ($3.71) EPS.

Several other analysts have also issued reports on NTLA. Bank of America restated a “neutral” rating on shares of Intellia Therapeutics in a research note on Monday. William Blair upgraded Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Monday. Wells Fargo & Company reduced their price objective on shares of Intellia Therapeutics from $17.00 to $12.00 and set an “equal weight” rating for the company in a research report on Friday, November 7th. Robert W. Baird set a $7.00 price objective on shares of Intellia Therapeutics in a report on Tuesday, January 27th. Finally, Barclays cut their target price on shares of Intellia Therapeutics from $24.00 to $14.00 and set an “overweight” rating for the company in a research note on Friday, November 7th. Eleven investment analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Intellia Therapeutics presently has a consensus rating of “Hold” and a consensus target price of $19.59.

Intellia Therapeutics Price Performance

Shares of NTLA stock opened at $13.82 on Tuesday. The company has a fifty day moving average price of $12.17 and a two-hundred day moving average price of $13.10. Intellia Therapeutics has a one year low of $5.90 and a one year high of $28.25. The stock has a market cap of $1.63 billion, a P/E ratio of -3.61 and a beta of 2.10.

Intellia Therapeutics (NASDAQ:NTLA) last issued its earnings results on Thursday, February 26th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.16. Intellia Therapeutics had a negative net margin of 609.85% and a negative return on equity of 56.81%. The company had revenue of $23.02 million for the quarter, compared to analysts’ expectations of $12.17 million. During the same period in the prior year, the firm earned ($1.27) EPS. Intellia Therapeutics’s quarterly revenue was up 78.4% compared to the same quarter last year. As a group, equities research analysts anticipate that Intellia Therapeutics will post -5.07 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Birgit C. Schultes sold 8,508 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was sold at an average price of $9.21, for a total value of $78,358.68. Following the transaction, the executive vice president owned 98,533 shares in the company, valued at approximately $907,488.93. This trade represents a 7.95% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP James Basta sold 10,397 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was sold at an average price of $9.21, for a total transaction of $95,756.37. Following the sale, the executive vice president directly owned 101,528 shares of the company’s stock, valued at $935,072.88. This represents a 9.29% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 53,051 shares of company stock valued at $488,600 over the last 90 days. 3.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Intellia Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in NTLA. Virtu Financial LLC bought a new stake in shares of Intellia Therapeutics during the 4th quarter worth approximately $245,000. Invesco Ltd. raised its position in Intellia Therapeutics by 5.8% during the fourth quarter. Invesco Ltd. now owns 433,290 shares of the company’s stock valued at $3,895,000 after purchasing an additional 23,870 shares in the last quarter. Axxcess Wealth Management LLC lifted its stake in Intellia Therapeutics by 20.1% during the fourth quarter. Axxcess Wealth Management LLC now owns 21,399 shares of the company’s stock worth $192,000 after purchasing an additional 3,583 shares during the last quarter. Mercer Global Advisors Inc. ADV acquired a new stake in shares of Intellia Therapeutics in the 4th quarter valued at $90,000. Finally, XTX Topco Ltd acquired a new stake in shares of Intellia Therapeutics in the 4th quarter valued at $402,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.

Intellia Therapeutics News Summary

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: FDA lifts clinical holds / allows second in‑human trial to resume, removing a major regulatory overhang and clearing Intellia to restart an important gene‑editing program. Read More. Read More.
• Positive Sentiment: Multiple analyst upgrades and target increases (JonesTrading to Buy, Leerink & HC Wainwright bumping targets, William Blair upgrade to Outperform) have supported sentiment and likely drove buying interest. JonesTrading set a $29 PT; HC Wainwright raised its PT to $30. Read More. Read More.
• Positive Sentiment: Intellia presented longer‑term clinical data for lonvoguran (lonvo‑z) at AAAAI showing multi‑year follow‑up after a one‑time dose — reinforces the durability narrative for a key therapeutic candidate. Read More.
• Positive Sentiment: High‑profile investor interest: Cathie Wood’s Ark (coverage piece) noted buying activity in beaten‑up growth names, including Intellia — a potential source of additional demand from momentum/growth investors. Read More.
• Neutral Sentiment: Other broker moves mixed: RBC, Wells Fargo and others nudged targets modestly higher (to ~$15), while Canaccord cut its target from $54 to $48 — consensus remains wide, reflecting varying views on timelines and commercialization risk. Read More.
• Negative Sentiment: HC Wainwright trimmed near‑term EPS estimates across several 2026 quarters and lowered full‑year forecasts slightly even while maintaining a Buy and a $30 PT — a reminder analysts expect continued cash burn and negative earnings into 2026. This raises execution risk and could limit multiple expansion. Read More.

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.